CliffBio
biologic

Elaprase

idursulfase

Loss of exclusivityJuly 2018projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameElaprase
Active ingredientidursulfase
Strength6MG/3ML (2MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2006
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Elaprase patent cliff — loss of exclusivity July 2018 | CliffBio